See more : PolyMet Mining Corp. (POM.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Verisante Technology Inc. (VRSEF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verisante Technology Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Orange Tour Cultural Holding Limited (8627.HK) Income Statement Analysis – Financial Results
- Bangkok Airways Public Company Limited (BA-R.BK) Income Statement Analysis – Financial Results
- DynaResource, Inc. (DYNR) Income Statement Analysis – Financial Results
- Charm Engineering Co.,Ltd. (009310.KS) Income Statement Analysis – Financial Results
- Delota Corp. (SYDRF) Income Statement Analysis – Financial Results
Verisante Technology Inc. (VRSEF)
About Verisante Technology Inc.
Verisante Technology Inc. does not have significant operations. Previously, it was involved in the design and manufacture of innovative cancer diagnostic devices. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology Inc. in January 2011. The company was incorporated in 2006 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.40K | 139.01K | 218.82K | 775.30K | 0.00 | 2.25K | 11.41K | 30.46K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 98.00 | 520.06K | 688.00 | 66.98K | 66.99K | 504.84K | 0.00 | 0.00 | 8.64K | 7.28K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -98.00 | -520.06K | 25.71K | 72.03K | 151.83K | 270.47K | 0.00 | 2.25K | 2.77K | 23.18K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 97.39% | 51.81% | 69.39% | 34.89% | 0.00% | 100.00% | 24.27% | 76.10% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.66K | 5.39K | 108.23K | 45.57K | 108.57K | 51.53K | 6.67K | 214.62K | 285.45K | 369.82K |
| General & Administrative | 123.66K | 283.65K | 192.25K | 159.36K | 154.54K | 321.33K | 580.77K | 612.60K | 1.27M | 2.32M | 3.50M | 2.55M | 3.29M | 1.33M | 836.74K | 557.22K |
| Selling & Marketing | 4.42K | 4.34K | 0.00 | 0.00 | 156.09K | 14.56K | 6.42K | 0.00 | 7.02K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 128.08K | 287.99K | 192.25K | 159.36K | 156.24K | 335.88K | 600.96K | 612.60K | 1.27M | 2.32M | 3.50M | 2.55M | 3.29M | 1.33M | 836.74K | 557.22K |
| Other Expenses | 8.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -845.89K | -34.56K | -24.59K | 0.00 | 0.00 | 0.00 | -1.74K | 160.02K | 264.33K | 40.45K |
| Operating Expenses | 136.27K | 287.99K | 192.25K | 159.36K | 156.24K | 335.88K | 1.45M | 1.54M | 2.48M | 3.50M | 4.67M | 3.33M | 3.56M | 1.65M | 1.15M | 931.20K |
| Cost & Expenses | 136.27K | 287.99K | 192.25K | 159.36K | 156.24K | 335.98K | 1.97M | 1.54M | 2.54M | 3.56M | 5.18M | 3.33M | 3.56M | 1.66M | 1.15M | 931.20K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 3.49K | 33.64K | 41.03K | 0.00 | 0.00 | 5.66K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.86K | 0.00 | 0.00 | 0.00 | 0.00 | 360.00 | 3.71K | 31.00 |
| Depreciation & Amortization | 128.08K | 287.99K | 184.48K | 151.40K | 98.00 | 98.00 | 520.06K | 924.40K | 1.10M | 1.13M | 1.06M | 727.80K | 263.44K | 103.56K | 23.38K | 4.16K |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -154.45K | -321.33K | -1.44M | -717.18K | -1.27M | -2.10M | -3.85M | -2.39M | -3.29M | -1.63M | -1.10M | -927.04K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,246.00% | -940.41% | -1,064.12% | -366.64% | 0.00% | -144,965.98% | -13,528.53% | -3,608.15% | 0.00% |
| Operating Income | -136.27K | -287.99K | -192.25K | -159.36K | -156.24K | -335.98K | -1.97M | -1.52M | -2.41M | -3.35M | -4.91M | -3.54M | -3.56M | -1.65M | -1.13M | -931.23K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,747.53% | -1,734.44% | -1,529.05% | -633.18% | 0.00% | -158,159.76% | -14,439.43% | -3,697.08% | 0.00% |
| Total Other Income/Expenses | 45.74K | 1.49M | 0.00 | 115.40K | 106.61K | 767.35K | -1.16M | -124.24K | 21.45K | 105.18K | 12.96K | 33.68K | 6.01K | 249.67K | 264.33K | 40.45K |
| Income Before Tax | -90.53K | 1.20M | -192.25K | -43.96K | -49.64K | 431.37K | -2.28M | -1.64M | -2.39M | -3.23M | -4.90M | -3.51M | -3.59M | -1.49M | -861.76K | -890.78K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,218.13% | -1,719.00% | -1,477.68% | -631.51% | 0.00% | -159,717.03% | -13,036.87% | -2,829.25% | 0.00% |
| Income Tax Expense | 0.00 | -1.72M | -186.48 | -321.69K | -0.10 | 2.00 | -3.00 | 0.00 | 14.86K | -112.39K | 495.30K | 177.97K | -7.75K | -2.41K | 3.71K | -5.63K |
| Net Income | -90.53K | 1.20M | -192.25K | -43.96K | -49.64K | 431.37K | -2.28M | -1.64M | -2.39M | -3.23M | -4.90M | -3.51M | -3.55M | -1.48M | -861.76K | -885.12K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,218.13% | -1,719.00% | -1,477.68% | -631.51% | 0.00% | -157,892.53% | -13,012.55% | -2,829.25% | 0.00% |
| EPS | 0.00 | 0.07 | -0.02 | 0.00 | -0.01 | 0.04 | -0.24 | -0.17 | -0.26 | -0.40 | -0.68 | -0.54 | -0.65 | -0.43 | -0.35 | -0.42 |
| EPS Diluted | 0.00 | 0.07 | -0.02 | 0.00 | -0.01 | 0.04 | -0.24 | -0.17 | -0.26 | -0.40 | -0.68 | -0.54 | -0.65 | -0.43 | -0.35 | -0.42 |
| Weighted Avg Shares Out | 34.08M | 16.51M | 9.86M | 9.86M | 9.86M | 9.86M | 9.65M | 9.43M | 9.06M | 8.17M | 7.25M | 6.51M | 5.47M | 3.45M | 2.50M | 2.12M |
| Weighted Avg Shares Out (Dil) | 34.07M | 16.51M | 9.86M | 9.86M | 9.86M | 9.86M | 9.65M | 9.43M | 9.06M | 8.17M | 7.25M | 6.51M | 5.47M | 3.45M | 2.50M | 2.12M |
Verisante Technology, Inc. Announces Update to Proposed RTO with SunRegen Healthcare AG
VANCOUVER, BC / ACCESSWIRE / October 31, 2024 / Verisante Technology, Inc. (TSXV:VER.H) ("Verisante") is pleased to announce a transaction update further to it's initial news release dated August 12, 2024, that it has entered into a binding Letter of...
Verisante Technology, Inc. Announces Proposed RTO with SunRegen Healthcare AG
VANCOUVER, BC / ACCESSWIRE / August 13, 2024 / Verisante Technology, Inc. (TSX-V:VER.H) ("Verisante") is pleased to announce that it has entered into a binding Letter of Intent ("LOI") dated August 12, 2024, to acquire a 100% interest in SunRegen...
Verisante Technology, Inc. Announces Exchange Acceptance of Shares for Debt Transaction
VANCOUVER, BC / ACCESSWIRE / March 30, 2024 / Verisante Technology, Inc. (TSX-V:VER.H) (the "Company") previously announced on March 14, 2024, that it had agreed to convert certain payables owed to Creditors into common shares in the capital of the...
Verisante Technology, Inc. Announces Shares for Debt Agreements
VANCOUVER, BC / ACCESSWIRE / March 14, 2024 / Verisante Technology, Inc. (TSXV:VER.H) (the "Company") is pleased to announce it has agreed to convert certain payables owed to Creditors into common shares in the capital of the Company (the "Settlement...
Verisante Technology, Inc. Announces 2023 AGM Results
VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / Verisante Technology, Inc. (TSXV:VER.H) (the "Company") is pleased to announce that at the 2023 Annual General Meeting held on December 18, 2023, in Vancouver, British Columbia, the Company's shareholders voted in...
Verisante Technology, Inc. Announces Exchange Approval for Shares for Debt Transaction
VANCOUVER, BC / ACCESSWIRE / October 5, 2023 / Verisante Technology, Inc. (TSXV:VER.H) (the "Company") previously announced on September 7, 2023, that it had agreed to convert certain payables owed to Creditors into common shares in the capital of the...
Source: https://incomestatements.info
Category: Stock Reports